Painreform is trading 6.45% down at $0.73 in pre-market; no new company-specific announcement explaining the October 29 move surfaced in the search. - The latest identified company update, on October 23, covered cash, plans for a Phase 2 trial and an AI data-center opportunity. - Nasdaq futures were down around 0.9% amid tech weakness, but there is no clear evidence this explains Painreform’s decline.